Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Disease progression? 313 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 313 reports of Disease progression have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 3.2% of all adverse event reports for BRENTUXIMAB VEDOTIN.

313
Reports of Disease progression with BRENTUXIMAB VEDOTIN
3.2%
of all BRENTUXIMAB VEDOTIN reports
98
Deaths
44
Hospitalizations

How Dangerous Is Disease progression From BRENTUXIMAB VEDOTIN?

Of the 313 reports, 98 (31.3%) resulted in death, 44 (14.1%) required hospitalization, and 7 (2.2%) were considered life-threatening.

Is Disease progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 313 reports have been filed with the FAERS database.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Disease progression?

RITUXIMAB (7,282) CYCLOPHOSPHAMIDE (7,100) DOXORUBICIN (6,165) VINCRISTINE (5,252) PREDNISONE (5,096) BEVACIZUMAB (4,653) DEXAMETHASONE (4,545) CARBOPLATIN (4,538) CAPECITABINE (3,808) ETOPOSIDE (3,776)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Disease progression Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Disease progression Reports All Drugs Causing Disease progression BRENTUXIMAB VEDOTIN Demographics